NCT06294548 - A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 29, 2025

Primary Completion Date

January 30, 2028

Study Completion Date

August 28, 2028

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Valemetostat

Valemetostat is an inhibitor of the enzymes enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2).

DRUG

Atezolizumab

Atezolizumab is commercially available. Atezolizumab combined with bevacizumab is approved for frontline treatment of advanced HCC based on IMbrave150 clinical trial. It will be administered as per the package insert and institutional standards.

DRUG

Bevacizumab

Bevacizumab is commercially available. Bevacizumab combined with atezolizumab is approved for frontline treatment of advanced HCC based on IMbrave150 clinical trial. It will be administered as per the package insert and institutional standards.

Trial Locations (1)

35294

RECRUITING

University of Alabama at Birmingham, Birmingham

All Listed Sponsors

lead

University of Alabama at Birmingham

OTHER